Production (Stage)
Cytophage Technologies Ltd.
CYTO.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -20.81% | 8.56% | -- | -- | -- |
| Depreciation & Amortization | 30.20% | 35.98% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.13% | 2.24% | -- | -- | -- |
| Operating Income | 15.13% | -2.24% | -- | -- | -- |
| Income Before Tax | 40.43% | -69.95% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 40.43% | -69.95% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.43% | -69.95% | -- | -- | -- |
| EBIT | 15.13% | -2.24% | -- | -- | -- |
| EBITDA | 16.67% | -0.86% | -- | -- | -- |
| EPS Basic | 48.78% | -40.00% | -- | -- | -- |
| Normalized Basic EPS | 24.86% | 11.02% | -- | -- | -- |
| EPS Diluted | 50.74% | -37.40% | -- | -- | -- |
| Normalized Diluted EPS | 24.86% | 11.02% | -- | -- | -- |
| Average Basic Shares Outstanding | 21.37% | 24.43% | -- | -- | -- |
| Average Diluted Shares Outstanding | 21.37% | 24.43% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |